Workflow
Bohui Innovation(300318)
icon
Search documents
博晖创新(300318) - 2020 Q2 - 季度财报
2020-08-27 16:00
```markdown [Important Notice, Table of Contents, and Definitions](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA%E3%80%81%E7%9B%AE%E5%BD%95%E5%92%8C%E9%87%8A%E4%B9%89) This section provides an overview of the report's structure, including important disclaimers, the table of contents, and definitions of key terms [Important Notice](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) The company's management guarantees the truthfulness and completeness of this semi-annual report, with no plans for profit distribution or capital reserve conversion during the period - The company's management guarantees the truthfulness, accuracy, and completeness of the report content and assumes legal responsibility[3](index=3&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[5](index=5&type=chunk) [Table of Contents](index=3&type=section&id=%E7%9B%AE%E5%BD%95) This section outlines the report's overall structure, covering twelve main parts from company overview to financial statements [Definitions](index=4&type=section&id=%E9%87%8A%E4%B9%89) This section defines specific terms, abbreviations, and professional jargon used in the report for investor clarity, including company entities and key products [Company Profile and Key Financial Indicators](index=5&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section introduces the company's profile and key financial indicators, including its basic information and performance metrics [Company Profile](index=5&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B) Beijing Bohui Innovation Biotechnology Co., Ltd. (stock code: 300318) is listed on the Shenzhen Stock Exchange, with Zhai Xiaofeng as its legal representative | Item | Information | | :--- | :--- | | Stock Abbreviation | Bohui Innovation | | Stock Code | 300318 | | Listing Exchange | Shenzhen Stock Exchange | | Legal Representative | Zhai Xiaofeng | [Key Accounting Data and Financial Indicators](index=6&type=section&id=%E5%9B%9B%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) During the reporting period, revenue decreased by 7.89% year-over-year, and net profit attributable to shareholders turned to a loss, declining by 1,147.09%, while operating cash flow significantly improved by 196.21% and total assets grew by 34.74% | Indicator | Current Period | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (Million Yuan) | 270.78 | 293.96 | -7.89% | | Net Profit Attributable to Shareholders (Million Yuan) | -15.95 | 1.52 | -1,147.09% | | Net Cash Flow from Operating Activities (Million Yuan) | 49.87 | -51.83 | 196.21% | | Basic EPS (Yuan/Share) | -0.0195 | 0.0019 | -1,126.32% | | **Indicator** | **Period-End** | **Prior Year-End** | **YoY Change** | | Total Assets (Billion Yuan) | 3.63 | 2.69 | 34.74% | | Net Assets Attributable to Shareholders (Billion Yuan) | 1.27 | 1.03 | 23.58% | [Non-Recurring Gains and Losses](index=7&type=section&id=%E5%85%AD%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%8F%8A%E9%87%91%E9%A2%9D) Non-recurring gains and losses totaled 0.95 million Yuan, primarily comprising government subsidies of 2.91 million Yuan and net non-operating and investment-related losses | Item | Amount (Million Yuan) | | :--- | :--- | | Government Subsidies | 2.91 | | Net Other Non-Operating Income and Expenses | -1.30 | | Fair Value Change Gains and Losses from Trading Financial Assets | -0.83 | | Gains and Losses from Disposal of Non-Current Assets | 0.36 | | **Total** | **0.95** | [Business Overview](index=8&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E5%85%AC%E5%8F%B8%E4%B8%9A%E5%8A%A1%E6%A6%82%E8%A6%81) This section details the company's core businesses, significant asset changes, and competitive advantages [Main Businesses During the Reporting Period](index=8&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E4%BB%8E%E4%BA%8B%E7%9A%84%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1) The company's main businesses include testing and diagnostics, focusing on in-vitro diagnostic products like trace element and HPV nucleic acid detection systems, and blood products, managed by subsidiaries Hebei Daan and Guangdong Weilun, offering human albumin and immunoglobulins [Testing and Diagnostics Business](index=8&type=section&id=1%E3%80%81%E6%A3%80%E9%AA%8C%E6%A3%80%E6%B5%8B%E4%B8%9A%E5%8A%A1) The core testing and diagnostics products are closed-system human trace element detection and microfluidic nucleic acid chip-based HPV detection, with stable market presence and rapid growth respectively, driven by instrument and reagent sales - The company's testing and diagnostics business primarily offers human trace element detection systems and HPV detection products, both closed-system solutions[25](index=25&type=chunk)[26](index=26&type=chunk) - The HPV product, leveraging the company's unique microfluidic nucleic acid chip technology, achieves fully automated nucleic acid molecular detection, making it the first fully automated nucleic acid molecular detection product in China[26](index=26&type=chunk) [Blood Products Business](index=9&type=section&id=2%E3%80%81%E8%A1%80%E6%B6%B2%E5%88%B6%E5%93%81%E4%B8%9A%E5%8A%A1) Blood products business, operated by Hebei Daan and Guangdong Weilun, includes albumin, immunoglobulins, and coagulation factors, relying on plasma stations for raw materials and strict batch release, with sales through distribution and direct channels - The blood products business is operated by subsidiaries Hebei Daan and Guangdong Weilun, with raw plasma supplied by their affiliated plasma collection stations[29](index=29&type=chunk)[30](index=30&type=chunk) | Category | Main Varieties | Application Area | | :--- | :--- | :--- | | Albumin | Human Albumin | Regulates plasma osmotic pressure, used in oncology, liver disease treatment | | Immunoglobulin | Human Immunoglobulin, Intravenous Human Immunoglobulin, etc | Treatment of immune diseases, passive immunization against infectious diseases | | Coagulation Factors | Human Prothrombin Complex | Used for treating coagulation factor deficiencies | [Significant Changes in Major Assets](index=12&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%BB%E8%A6%81%E8%B5%84%E4%BA%A7%E9%87%8D%E5%A4%A7%E5%8F%98%E5%8C%96%E6%83%85%E5%86%B5) Major assets saw significant changes due to the merger of subsidiary Hebei Daan with Zhongke Bio, leading to substantial increases in fixed assets, intangible assets, construction in progress, and goodwill, while cash grew from Hebei Daan's capital injection | Major Asset | Period-End vs. Year-Start Change | Explanation of Significant Change | | :--- | :--- | :--- | | Fixed Assets | +51.96% | Primarily due to the merger with Zhongke Bio | | Intangible Assets | +66.18% | Primarily due to the merger with Zhongke Bio | | Construction in Progress | +46.03% | Primarily due to the merger with Zhongke Bio and the capitalization of the company's Phase II base | | Monetary Funds | +329.4% | Primarily due to capital injection received by Hebei Daan | | Goodwill | +41.16% | Primarily due to new goodwill from the merger with Zhongke Bio | [Analysis of Core Competencies](index=13&type=section&id=%E4%B8%89%E3%80%81%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company's core competencies include continuous technological innovation, high-barrier products, effective quality management, and talent development, with exclusive microfluidic chip technology in diagnostics and strengthening R&D in blood products, adhering to GMP standards - The company has undertaken multiple national-level major scientific research projects in testing and diagnostics, holding exclusive patented technology for its microfluidic chip molecular diagnostic platform[49](index=49&type=chunk)[50](index=50&type=chunk) - R&D in blood products advanced, with subsidiary Hebei Daan obtaining drug registration certificates for intravenous human immunoglobulin and human prothrombin complex in July 2020[49](index=49&type=chunk) - The company prioritizes quality system development, having obtained medical device GMP, ISO13485, and ISO9001 certifications, with blood product manufacturing facilities compliant with GMP standards[51](index=51&type=chunk)[52](index=52&type=chunk) [Management Discussion and Analysis](index=15&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) This section discusses the company's operational performance, financial status, and risk management strategies [Overview](index=15&type=section&id=%E4%B8%80%E3%80%81%E6%A6%82%E8%BF%B0) In H1 2020, revenue decreased by 7.89% to 271 million Yuan, and net profit attributable to parent company was -15.95 million Yuan, down 1147.09% due to COVID-19 impacting testing and diagnostics, while blood products grew by 16%, with Q2 losses narrowing - Testing and diagnostics business: Achieved main business revenue of **102 million Yuan**, a year-over-year decrease of **31.35%**, primarily due to reduced hospital health screening volumes during the pandemic[57](index=57&type=chunk) - Blood products business: Achieved main business revenue of **169 million Yuan**, a year-over-year increase of **15.98%**, primarily due to a significant sales increase of intravenous human immunoglobulin produced by Guangdong Weilun as an epidemic prevention drug[61](index=61&type=chunk) - R&D made positive progress, with Hebei Daan obtaining drug registration certificates for intravenous human immunoglobulin and human prothrombin complex in July 2020, enhancing its product structure[62](index=62&type=chunk) - Hebei Daan completed a capital increase and acquisition of **72% equity** in Zhongke Bio, strengthening capital and optimizing the competitive landscape[62](index=62&type=chunk) [Analysis of Main Business Operations](index=20&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) Main business operations showed divergence due to the pandemic, with instrument, software, reagent, and albumin revenues declining by 20-35%, while intravenous immunoglobulin (IVIG) revenue nearly doubled, despite a decrease in its gross margin due to rising costs | Item | Current Period | Prior Year Period | YoY Change | Main Reason | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue (Million Yuan) | 271 | 294 | -7.89% | COVID-19 impacted testing business revenue | | Financial Expenses (Million Yuan) | 17.38 | 11.72 | +48.22% | Increase in interest expenses on borrowings | | R&D Investment (Million Yuan) | 41.61 | 34.58 | +20.32% | - | | Net Cash Flow from Operating Activities (Million Yuan) | 49.87 | -51.83 | +196.21% | Strengthened collection management and expenditure control | | Product/Service | Operating Revenue (Million Yuan) | Gross Margin | Operating Revenue YoY Change | | :--- | :--- | :--- | :--- | | Instruments and Software | 32.99 | 30.96% | -30.99% | | Reagents | 55.26 | 78.44% | -34.18% | | Albumin | 80.49 | 24.88% | -23.25% | | IVIG | 63.90 | 40.94% | +99.89% | [Analysis of Non-Core Business Operations](index=21&type=section&id=%E4%B8%89%E3%80%81%E9%9D%9E%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) Non-core operations negatively impacted profit, with investment losses of 0.91 million Yuan from wealth management and derivatives, and non-operating expenses of 1.45 million Yuan due to COVID-19 donations - Investment income was **-0.91 million Yuan**, mainly due to losses from wealth management products and matured forward foreign exchange and risk option contracts[73](index=73&type=chunk) - Non-operating expenses totaled **1.45 million Yuan**, primarily due to donations for the COVID-19 pandemic[74](index=74&type=chunk) [Analysis of Assets and Liabilities](index=22&type=section&id=%E5%9B%9B%E3%80%81%E8%B5%84%E4%BA%A7%E3%80%81%E8%B4%9F%E5%80%BA%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) At period-end, the company's asset and liability structure significantly changed, with non-current assets like fixed assets and construction in progress increasing, cash substantially rising, inventory share decreasing, and short-term debt increasing while long-term debt decreased [Analysis of Investment Activities](index=23&type=section&id=%E4%BA%94%E3%80%81%E6%8A%95%E8%B5%84%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) Investment increased by 169.63% year-over-year, primarily for capital injection related to Hebei Daan equity compensation, and the company acquired 72% of Zhongke Bio for 41.76 million Yuan via non-monetary asset exchange, with the deal closed - Investment during the reporting period was **207 million Yuan**, a year-over-year increase of **169.63%**, mainly for capital injection related to Mr. Du Jiangtao's compensation to Hebei Daan on behalf of Yunnan Watson[79](index=79&type=chunk) - Acquired **72% equity** in Zhongke Bio-Pharmaceutical Co., Ltd. for **41.76 million Yuan** through non-monetary asset exchange, with equity transfer completed[81](index=81&type=chunk) [Analysis of Major Holding and Participating Companies](index=25&type=section&id=%E4%B8%83%E3%80%81%E4%B8%BB%E8%A6%81%E6%8E%A7%E8%82%A1%E5%8F%82%E8%82%A1%E5%85%AC%E5%8F%B8%E5%88%86%E6%9E%90) Key subsidiaries showed mixed performance, with blood product subsidiary Hebei Daan achieving a net profit of 16.31 million Yuan, while Guangdong Weilun incurred a loss of 8.26 million Yuan, and US-based testing and diagnostics subsidiary Advion, Inc. reported a loss of 14.12 million Yuan | Company Name | Main Business | Operating Revenue (Million Yuan) | Net Profit (Million Yuan) | | :--- | :--- | :--- | :--- | | Hebei Daan Pharmaceutical Co., Ltd. | Blood Products | 100.36 | 16.31 | | Guangdong Weilun Bio-Pharmaceutical Co., Ltd. | Blood Products | 115.16 | -8.26 | | Advion,Inc. | Testing and Diagnostics | 31.60 | -14.12 | [Risks Faced by the Company and Countermeasures](index=25&type=section&id=%E4%B9%9D%E3%80%81%E5%85%AC%E5%8F%B8%E9%9D%A2%E4%B8%B4%E7%9A%84%E9%A3%8E%E9%99%A9%E5%92%8C%E5%BA%94%E5%AF%B9%E6%8E%AA%E6%96%BD) The company faces operational risks from the ongoing COVID-19 pandemic, particularly impacting testing and diagnostics, potential product safety risks in blood products, regulatory risks for plasma stations, and R&D failure risks for medical devices, addressed by strengthening management, quality systems, plasma station digitalization, and advanced R&D tools - COVID-19 impact: Testing and diagnostics revenue decreased, and plasma collection was affected. Countermeasures include strengthening scientific management and cost-saving initiatives[89](index=89&type=chunk)[90](index=90&type=chunk) - Product safety risk: Blood products use special raw materials, posing potential risks of unknown virus transmission. Countermeasures include improving the quality management system and strictly adhering to GMP standards[91](index=91&type=chunk)[92](index=92&type=chunk) - Regulatory risk: Plasma collection station operations require continuous standardization, with risks of penalties due to management oversight. Countermeasures include increasing IT investment for full traceability[93](index=93&type=chunk) - R&D risk: Medical device R&D has long cycles and high difficulty, potentially facing failure risks. Countermeasures include strengthening project management to improve success rates[94](index=94&type=chunk)[95](index=95&type=chunk) [Significant Matters](index=27&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section highlights significant events, including major related-party transactions and subsidiary developments [Major Related-Party Transactions](index=29&type=section&id=%E5%8D%81%E4%B8%89%E3%80%81%E9%87%8D%E5%A4%A7%E5%85%B3%E8%81%94%E4%BA%A4%E6%98%93) Several major related-party transactions occurred, including 7.69 million Yuan in product sales to Inner Mongolia Junzheng Group for donations, a planned share issuance to Zhuhai Aosen (controlled by the actual controller) for asset acquisition, and a capital increase for Hebei Daan involving related parties, where the company waived its pre-emptive rights - Subsidiaries Guangdong Weilun and Hebei Daan signed drug purchase and sales contracts totaling **7.69 million Yuan** with related party Inner Mongolia Junzheng Group for public welfare donations to combat the epidemic[113](index=113&type=chunk) - The company plans to issue shares to Zhuhai Aosen, controlled by actual controller Mr. Du Jiangtao, to acquire assets and raise supporting funds[114](index=114&type=chunk) - The company introduced external investors (including related party Shengtai Technology) for a capital increase in subsidiary Hebei Daan and waived its pre-emptive rights[115](index=115&type=chunk) [Significant Matters of Subsidiaries](index=34&type=section&id=%E5%8D%81%E4%B8%83%E3%80%81%E5%85%AC%E5%8F%B8%E5%AD%90%E5%85%AC%E5%8F%B8%E9%87%8D%E5%A4%A7%E4%BA%8B%E9%A1%B9) Subsidiaries saw several significant developments, including Hebei Daan's acquisition of 72% of Zhongke Bio (human rabies vaccine producer), a provincial high-tech industrialization project for Hebei Daan, and the expiration of a plasma station license for Guangdong Weilun in February 2020 - Subsidiary Hebei Daan completed the acquisition of **72% equity** in Zhongke Bio, which primarily produces human rabies vaccine[132](index=132&type=chunk) [Share Changes and Shareholder Information](index=35&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) This section outlines changes in share capital and shareholder structure, including major shareholders' holdings [Share Capital Changes](index=35&type=section&id=%E4%B8%80%E3%80%81%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, the total share capital remained at 816,900,495 shares, but the share structure changed as 12,677,034 restricted shares converted to unrestricted shares due to automatic unlocking for senior executives, reducing the restricted share percentage from 11.31% to 9.75% - Total share capital remained unchanged at **816,900,495 shares**[137](index=137&type=chunk) - Restricted shares decreased by **12,677,034 shares**, with a corresponding increase in unrestricted shares, due to automatic unlocking for senior executives[137](index=137&type=chunk) [Shareholder Numbers and Shareholding Structure](index=36&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5) As of the end of the reporting period, the company had 27,670 common shareholders, with the actual controller Du Jiangtao and his spouse Hao Hong collectively holding over 51% of shares, and the top ten shareholders primarily being natural persons with a stable structure | Shareholder Name | Shareholding Percentage | Number of Shares Held | | :--- | :--- | :--- | | Du Jiangtao | 39.03% | 318,811,388 | | Hao Hong | 12.59% | 102,809,951 | | Yang Qi | 7.48% | 61,123,211 | | Mei Yingjun | 3.55% | 29,034,177 | | Du Jianghong | 3.00% | 24,478,560 | - Among the top ten shareholders, Du Jiangtao and Hao Hong are spouses, and Du Jiangtao and Du Jianghong are siblings[143](index=143&type=chunk) [Directors, Supervisors, and Senior Management](index=41&type=section&id=%E7%AC%AC%E4%B9%9D%E8%8A%82%20%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E6%83%85%E5%86%B5) This section details changes in the board of directors, supervisors, and senior management personnel [Changes in Directors, Supervisors, and Senior Management](index=42&type=section&id=%E4%BA%8C%E3%80%81%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, the board, supervisory board, and senior management underwent significant changes due to elections, resignations, and term expirations, with new vice chairmen, directors, general managers, independent directors, supervisors, and deputy general managers appointed - Appointments: Mr. Jiang Yan was appointed General Manager, Mr. Wang Wei and Mr. Zhang Lei as Deputy General Managers, and Mr. Dong Haifeng as Chief Financial Officer[157](index=157&type=chunk) - Board and management changes: Former Chairman Lu Xinqun, Director Yang Qi, and other executives departed due to term expiration. New members elected include Shen Zhiwei as Vice Chairman, Jiang Yan and Wang Wei as Directors, and Ban Jun and Zhang Xiaosu as Independent Directors[157](index=157&type=chunk) [Financial Report](index=44&type=section&id=%E7%AC%AC%E5%8D%81%E4%B8%80%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) This section presents the company's financial statements, including balance sheets, income statements, and cash flow statements [Financial Statements](index=44&type=section&id=%E4%BA%8C%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the company's unaudited consolidated and parent company financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in equity, reflecting H1 2020 financial position, operating results, and cash flows [Consolidated Balance Sheet](index=44&type=section&id=1%E3%80%81%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of June 30, 2020, total assets were 3.63 billion Yuan, up 34.74% from year-start, and total liabilities were 2.22 billion Yuan, up 34.95%, primarily due to the acquisition of Zhongke Bio and subsidiary capital injections, with equity attributable to parent company increasing by 23.58% to 1.27 billion Yuan | Item | June 30, 2020 (Billion Yuan) | December 31, 2019 (Billion Yuan) | | :--- | :--- | :--- | | Total Assets | 3.63 | 2.69 | | Total Liabilities | 2.22 | 1.64 | | Total Equity Attributable to Parent Company Owners | 1.27 | 1.03 | [Consolidated Income Statement](index=50&type=section&id=3%E3%80%81%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) In H1 2020, total operating revenue was 271 million Yuan, down 7.89%, with operating profit turning to a loss of -11.69 million Yuan, and net profit attributable to parent company significantly declining to -15.95 million Yuan from 1.52 million Yuan last year | Item | H1 2020 (Million Yuan) | H1 2019 (Million Yuan) | | :--- | :--- | :--- | | Total Operating Revenue | 270.78 | 293.96 | | Operating Profit | -11.69 | 8.67 | | Net Profit Attributable to Parent Company Owners | -15.95 | 1.52 | [Consolidated Cash Flow Statement](index=53&type=section&id=5%E3%80%81%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Operating cash flow significantly improved to 49.87 million Yuan from -51.83 million Yuan last year, while investing activities had a net outflow of 196 million Yuan for equity capital injections, and financing activities had a net inflow of 245 million Yuan from borrowings and capital contributions, increasing cash and cash equivalents to 129 million Yuan | Item | H1 2020 (Million Yuan) | H1 2019 (Million Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 49.87 | -51.83 | | Net Cash Flow from Investing Activities | -196.06 | -76.75 | | Net Cash Flow from Financing Activities | 245.39 | 63.98 | | Net Increase in Cash and Cash Equivalents | 98.93 | -64.67 | [Changes in Consolidation Scope](index=146&type=section&id=%E5%85%AB%E3%80%81%E5%90%88%E5%B9%B6%E8%8C%83%E5%9B%B4%E7%9A%84%E5%8F%98%E6%9B%B4) The consolidation scope changed due to a non-same-control business combination, with subsidiary Hebei Daan acquiring 72% of Zhongke Bio for 41.76 million Yuan via non-monetary asset exchange, consolidating it as of June 30, 2020, and generating 324 million Yuan in goodwill - Zhongke Bio-Pharmaceutical Co., Ltd. was included in the consolidation scope due to a non-same-control business combination[633](index=633&type=chunk) | Merger Cost Item | Amount (Million Yuan) | | :--- | :--- | | Fair Value of Non-Cash Assets | 41.76 | | Less: Fair Value Share of Identifiable Net Assets Acquired | -282.03 | | **Goodwill** | **323.79** | [Other Significant Matters](index=158&type=section&id=%E5%8D%81%E4%BA%94%E3%80%81%E5%85%B6%E4%BB%96%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) The company segmented its operations into testing and diagnostics and blood products; in H1 2020, the testing segment generated 102 million Yuan in revenue with an operating loss of -29.93 million Yuan, while the blood products segment generated 169 million Yuan in revenue with an operating profit of 18.24 million Yuan, showing divergent performance | Item | Testing & Diagnostics Segment (Million Yuan) | Blood Products Segment (Million Yuan) | | :--- | :--- | :--- | | Operating Revenue | 101.82 | 168.93 | | Operating Profit | -29.93 | 18.24 | | Net Profit | -29.12 | 12.83 | | Total Assets (Billion Yuan) | 2.28 | 2.19 | | Total Liabilities (Billion Yuan) | 0.77 | 1.49 | [Catalogue of Reference Documents](index=166&type=section&id=%E7%AC%AC%E5%8D%81%E4%BA%8C%E8%8A%82%20%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6%E7%9B%AE%E5%BD%95) This section lists reference documents available for inspection, including signed report texts by legal representatives and financial officers, original copies of all publicly disclosed documents, and announcements from the reporting period [Reference Documents](index=166&type=section&id=%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6) This section lists reference documents available for inspection, including signed report texts by legal representatives and financial officers, original copies of all publicly disclosed documents, and announcements from the reporting period ```
博晖创新(300318) - 2020 Q1 - 季度财报
2020-04-24 16:00
北京博晖创新生物技术股份有限公司 2020 年第一季度报告全文 北京博晖创新生物技术股份有限公司 2020 年第一季度报告 定 2020-03 2020 年 04 月 1 北京博晖创新生物技术股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入(元) | 139,506,502.75 | 134,580,507.88 | 3.66% | | 归属于上市公司股东的净利润(元) | -13,453,684.69 | -6,281,688.10 | -114.17% | | 归属于上市公司股东的扣除非经常性损 益的净利润(元) | -12,772,384.53 | -6,238,719.03 | -104.73% | | 经营活动产生的现金流量净额(元) | 21,810,011. ...
博晖创新(300318) - 2019 Q3 - 季度财报
2019-10-24 16:00
Financial Performance - Operating revenue for the reporting period was CNY 167,780,231.32, an increase of 4.70% year-on-year[8] - Net profit attributable to shareholders decreased by 47.21% to CNY 3,267,994.90[8] - Basic earnings per share were CNY 0.0040, down 47.37% compared to the same period last year[8] - Investment income for the period was CNY 156.52 million, reflecting a decrease from the previous year's CNY 352.18 million due to the recognition of equity compensation[20] - The total profit for the current period was ¥5,745,043.85, down from ¥11,139,909.37 in the previous period[42] - The net profit for Q3 2019 was CNY 8,627,171.12, a decrease of 69.9% from CNY 28,721,165.26 in the same period last year[50] - Comprehensive income for the current period totaled ¥3,981,748.75, down from ¥10,663,042.87 in the previous period[42] - The company's operating revenue for Q3 2019 was CNY 162,371,553.11, an increase of 8.3% compared to CNY 149,979,806.56 in Q3 2018[53] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,648,914,362.58, a decrease of 2.34% compared to the end of the previous year[8] - The company's total liabilities reached CNY 1,603,565,767.16, up from CNY 1,468,410,939.03, indicating a rise of 9.2%[33] - Current liabilities totaled CNY 1,264,644,733.62, compared to CNY 1,252,671,478.33 in the previous period, reflecting an increase of approximately 1.5%[33] - Long-term borrowings increased significantly to CNY 217,544,859.15 from CNY 106,100,000.00, representing a growth of 104.1%[33] - Cash and cash equivalents decreased by 75.10% compared to the beginning of the year, primarily due to a reduction in available working capital[19] - Cash and cash equivalents at the end of the period decreased to 25,521,698.75 CNY from 58,968,392.31 CNY, indicating a decline in liquidity[58] Shareholder Information - The company reported a total of 18,987 common shareholders at the end of the reporting period[12] - The top shareholder, Du Jiangtao, holds 39.03% of the shares, amounting to 318,811,388 shares[12] - The total equity attributable to shareholders decreased to CNY 1,019,953,617.76 from CNY 1,173,270,705.96, a decline of 13.1%[34] Cash Flow - The net cash flow from operating activities was CNY -43,150,496.29, a decrease of 30.56% year-on-year[8] - Cash flow from operating activities increased to CNY 510,538,187.72, compared to CNY 423,216,336.39 in Q3 2018[56] - Total cash inflow from financing activities increased to 657,376,480.66 CNY, compared to 366,786,408.00 CNY in the prior period, reflecting a significant rise in borrowing[58] - The total cash outflow for financing activities was 584,085,726.01 CNY, significantly higher than 267,100,332.36 CNY in the previous period, reflecting increased financial obligations[58] Expenses and Costs - Total operating costs increased to ¥160,986,669.70, up 7.9% from ¥149,145,891.68 in the previous period, with operating costs specifically rising to ¥86,500,089.70 from ¥77,413,394.21[41] - Financial expenses increased by CNY 4.30 million, a rise of 31.13%, mainly due to increased interest expenses from higher borrowings[20] - The company paid 160,698,149.87 CNY to employees, an increase from 131,378,035.09 CNY, reflecting higher labor costs[57] Research and Development - The company reported a significant increase in research and development expenses, totaling ¥13,008,593.64, compared to ¥12,952,626.87 in the previous period[41] - Research and development expenses rose to CNY 39,246,495.87, up 11.8% from CNY 35,089,152.21 in Q3 2018[53] Future Outlook - The company expects a significant decline in cumulative net profit compared to the same period last year, primarily due to reduced impacts from equity compensation and goodwill impairment[23] - The company plans to continue focusing on R&D and market expansion to improve future performance[50]
博晖创新(300318) - 2019 Q2 - 季度财报
2019-08-26 16:00
北京博晖创新生物技术股份有限公司 2019 年半年度报告全文 北京博晖创新生物技术股份有限公司 2019 年半年度报告 定 2019-04 2019 年 08 月 1 北京博晖创新生物技术股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别 和连带的法律责任。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明:保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利,不送红股,不以公积金转增股本。 2 | | | | 2019 | 年半年度报告 1 | | --- | --- | | 第一节 | 重要提示、释义 1 | | 第二节 | 公司简介和主要财务指标 4 | | 第三节 | 公司业务概要 6 | | 第四节 | 经营情况讨论与分析 10 | | 第五节 | 重要事项 14 | | 第六节 | 股份变动及股东情况 15 | | 第七节 | 优先股相关情况 16 ...
博晖创新(300318) - 2019 Q1 - 季度财报
2019-04-26 16:00
Financial Performance - Total revenue for Q1 2019 was ¥134,580,507.88, an increase of 4.62% compared to ¥128,637,899.74 in the same period last year[8] - Net profit attributable to shareholders was -¥6,281,688.10, a decrease of 183.42% from ¥7,530,601.21 in the previous year[8] - Basic earnings per share decreased by 183.70% to -¥0.0077 from ¥0.0092 in the same period last year[8] - Operating income increased by 4.62% year-on-year, with the parent company benefiting from an 18% increase in microfluidic product revenue[23] - The company reported a net operating loss of CNY -3,311,283.65 for Q1 2019, compared to a profit of CNY 10,316,428.21 in the previous year[41] - The net profit for Q1 2019 was a loss of CNY 4,365,383.99, compared to a profit of CNY 8,326,652.67 in Q1 2018, indicating a significant decline[43] - The total comprehensive income for Q1 2019 was a loss of CNY 5,010,249.33, compared to a gain of CNY 7,149,405.62 in Q1 2018[43] Cash Flow - Net cash flow from operating activities was -¥46,907,435.82, a decline of 27.37% compared to -¥36,828,618.07 in the previous year[8] - Cash flow from operating activities related to other payments increased by 59.56% year-on-year, attributed to higher sales and R&D expenses[21] - The operating cash flow for Q1 2019 was a net outflow of CNY 46,907,435.82, worsening from a net outflow of CNY 36,828,618.07 in the same period last year[50] - The net cash flow from operating activities was -20,815,200.73 RMB, compared to -6,609,913.82 RMB in the previous period, indicating a significant decline in operational cash flow[53] - The company received cash inflows from financing activities totaling 124,285,772.43 RMB, while cash outflows were 71,305,715.68 RMB, resulting in a net cash flow of 52,980,056.75 RMB from financing activities[51] - Cash inflows from investment activities were 23,000,000.00 RMB, while cash outflows were 37,493,636.90 RMB, leading to a net cash flow of -14,493,636.90 RMB from investment activities[54] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,747,072,246.19, an increase of 1.28% from ¥2,712,341,755.90 at the end of the previous year[8] - Total liabilities increased to CNY 1,031,430,007.15 in Q1 2019 from CNY 980,172,142.99 in the previous year, marking an increase of approximately 5.2%[40] - The company's total equity as of March 31, 2019, was CNY 1,625,734,396.21, slightly up from CNY 1,625,617,866.41 at the end of 2018[40] - The company’s total assets amounted to CNY 2.747 billion as of March 31, 2019, compared to CNY 2.712 billion at the end of 2018[34] - Total current assets amounted to CNY 675,172,919.44, with cash and cash equivalents at CNY 28,721,506.86[61] - Total non-current assets reached CNY 1,930,617,089.96, including long-term equity investments of CNY 1,511,338,284.19[61] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,892[12] - The company has not conducted an audit for the first quarter report, which may affect the reliability of the financial data presented[63] Operational Costs and Expenses - Total operating costs for Q1 2019 were CNY 138,047,954.69, up from CNY 118,503,228.43, indicating an increase of about 16.5% year-over-year[41] - Research and development expenses for Q1 2019 were CNY 13,196,333.60, compared to CNY 10,453,698.14 in the same period last year, indicating an increase of about 26.4%[41] - The company reported a decrease in income tax expenses by CNY 1.2772 million, a reduction of 57.38%, due to a decrease in total profit[20] - Financial expenses increased by CNY 2.2936 million, a growth of 62.17%, mainly due to increased interest expenses from bank loans and inter-company borrowings[20] - The company incurred financial expenses of CNY 3,876,400.23 in Q1 2019, compared to CNY 2,323,916.14 in Q1 2018, indicating increased borrowing costs[46] Other Financial Metrics - Other comprehensive income decreased by 782.47% year-on-year, primarily due to foreign currency translation adjustments[19] - Cash and cash equivalents increased to CNY 47,948,599.20 as of March 31, 2019, compared to CNY 28,721,506.86 at the end of 2018, reflecting a growth of approximately 67.2%[38] - The company reported sales revenue from goods and services of 42,863,089.85 RMB, an increase from 33,397,782.99 RMB in the previous period, representing a growth of approximately 28.5%[53] - The company reported other income of CNY 145,248.17 in Q1 2019, slightly down from CNY 152,707.91 in Q1 2018[46]
博晖创新(300318) - 2018 Q4 - 年度财报
2019-04-22 16:00
Financial Performance - The company's operating revenue for 2018 was CNY 622,093,848.04, representing a 40.19% increase compared to CNY 443,754,419.40 in 2017[15]. - The net profit attributable to shareholders for 2018 was CNY 69,438,286.13, a significant increase of 78.73% from CNY 38,850,990.10 in 2017[15]. - The basic earnings per share for 2018 was CNY 0.0848, up 78.15% from CNY 0.0476 in 2017[15]. - The company reported a net profit of CNY 137,976,966.72 for the year 2018, a decrease from CNY 319,713,808.01 in 2017, reflecting a decline of approximately 57%[21]. - The company achieved blood product revenue of CNY 326.84 million, a year-on-year increase of 76.56%[60]. - The total revenue for the reporting period was CNY 622.09 million, representing a 40.19% increase compared to CNY 443.75 million in the previous year[67]. Cash Flow and Investments - The net cash flow from operating activities for 2018 was -CNY 84,149,883.86, showing an improvement of 11.60% compared to -CNY 95,194,050.69 in 2017[15]. - Total operating cash inflow increased by 30.87% year-on-year to ¥612,020,524.38, primarily due to increased sales revenue[89]. - Total cash inflow from investing activities decreased by 53.16% year-on-year to ¥38,636,110.73, mainly due to increased cash flow from short-term idle fund management[90]. - Total cash outflow from investing activities decreased by 55.31% year-on-year to ¥86,292,266.70, with no significant investment activities in 2018[90]. - The significant difference between net cash flow from operating activities and net profit was mainly due to asset impairment provisions of ¥73,729,200 and fair value changes of -¥195,666,000[93]. Market and Industry Insights - The company operates in the in-vitro diagnostics (IVD) sector, which accounted for 13% of the global medical device market, with sales reaching USD 52.6 billion in 2017[30]. - The global IVD market size was approximately $60 billion in 2016, with an expected CAGR of about 5%, reaching $78.7 billion by 2021[1]. - China's IVD market size reached approximately 60 billion yuan in 2017, projected to grow to 72.3 billion yuan by 2019, with a CAGR of about 15% over the past five years[1]. - The concentration of the IVD industry in China is low, with over 600 companies, and the top 20 companies holding only about 30% market share, indicating opportunities for growth[5]. Research and Development - The company has developed a microfluidic chip control technology, which is a domestic innovation and internationally leading, with over 20 patents related to this technology[27]. - The company is actively developing new products, with several products approved for market, including rabies immunoglobulin and tetanus immunoglobulin[62]. - The number of R&D personnel increased to 104 in 2018, up from 101 in 2017 and 89 in 2016[83]. - The R&D investment for the year was ¥75,074,298.65, up from ¥58,590,685.81 in the previous year, indicating a growth of approximately 28.3%[84]. Shareholder and Dividend Information - The company plans to distribute cash dividends to shareholders at a rate of CNY 0 per 10 shares, with no bonus shares issued[5]. - The total cash dividend amount for 2018 was ¥0.00, with no shares distributed or increased[130]. - In 2018, the company achieved a net profit of ¥77,508,382.28, with a distributable profit of ¥352,982,877.38, but opted for no cash dividends, resulting in a 0.00% payout ratio[133]. - The company has maintained compliance with relevant laws and regulations regarding profit distribution and shareholder rights[137]. Operational Strategies - The company is focusing on expanding its blood products business and plans to open new plasma collection stations to enhance production capacity[133]. - The blood products business strategy aims to increase operational efficiency and seek reasonable acquisition opportunities to become a competitive player in the industry within 3-5 years[114]. - The company plans to enhance its marketing efforts by integrating sales from different regions and actively participating in drug bidding processes to increase market share[114]. - The company emphasizes the importance of quality control in its operations, establishing a comprehensive quality management system to mitigate risks associated with product safety[117]. Compliance and Commitments - The company has adhered to all commitments made by shareholders and related parties during the reporting period[140]. - No violations of commitments were reported by the company's actual controllers, shareholders, or related parties during the reporting period[140]. - The profit compensation agreement includes a formula for calculating the number of shares to be repurchased based on the difference between committed and actual profits[143].
博晖创新(300318) - 2018 Q3 - 季度财报
2018-10-22 16:00
所有董事均已出席了审议本次季报的董事会会议。 北京博晖创新生物技术股份有限公司 2018 年第三季度报告全文 北京博晖创新生物技术股份有限公司 2018 年第三季度报告 定 2018-06 2018 年 10 月 1 北京博晖创新生物技术股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和 连带的法律责任。 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产(元) | 2,531,023,016.65 | 2,737,468,431.65 | | -7.54% | | 归属于上市公司股东的净资产 | 1,113,852,920.84 | 1,474,242,334.41 | | -24.45% | | (元) | | | | | | | 本报告期 | 本报告期比上年同期 增减 | 年初至报告期末 | 年初至报告期末比上 年同期增减 | | 营业收入(元) | ...
博晖创新(300318) - 2018 Q2 - 季度财报
2018-08-13 16:00
北京博晖创新生物技术股份有限公司 2018 年半年度报告全文 北京博晖创新生物技术股份有限公司 2018 年半年度报告 定 2018-04 2018 年 08 月 1 北京博晖创新生物技术股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别 和连带的法律责任。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明:保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利,不送红股,不以公积金转增股本。 2 | 2018 | 年半年度报告 2 | | --- | --- | | 第一节 | 重要提示、释义 5 | | 第二节 | 公司简介和主要财务指标 5 | | 第三节 | 公司业务概要 8 | | 第四节 | 经营情况讨论与分析 17 | | 第五节 | 重要事项 28 | | 第六节 | 股份变动及股东情况 35 | | 第七节 | 优先股相关情况 39 | | 第 ...
博晖创新(300318) - 2018 Q1 - 季度财报
2018-04-25 16:00
北京博晖创新光电技术股份有限公司 2018 年第一季度报告全文 北京博晖创新光电技术股份有限公司 2018 年第一季度报告 定 2018-03 2018 年 04 月 1 北京博晖创新光电技术股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明:保证季度报告中财务报表的真实、准确、完整。 2 北京博晖创新光电技术股份有限公司 2018 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | 营业总收入(元) | 128,637,899.74 | 83,520,656.10 | | 54.02% | | 归属于上市公司 ...
博晖创新(300318) - 2017 Q4 - 年度财报(更新)
2018-04-24 16:00
北京博晖创新光电技术股份有限公司 2017 年年度报告全文 北京博晖创新光电技术股份有限公司 2017 年年度报告 定 2018-01 2018 年 04 月 1 北京博晖创新光电技术股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或重大遗漏,并承担个别和连 带的法律责任。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明:保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告内容中涉及的未来计划等前瞻性陈述因存在不确定性,不构成 公司对投资者的实质承诺,请投资者注意投资风险。 公司不存在因经营状况、 财务状况和持续盈利能力方面有严重不利影响的风险因素。有关公司可能面对 的风险及公司应对措施等详见本报告第四节"经营情况讨论与分析"中相关内 容。 公司经本次董事会审议通过的利润分配预案为:以 821,410,144 为基数,向 全体股东每 10 股派发现金红利 0.05 元(含税),送红股 0 股(含税) ...